Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 705–707 | Cite as

Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with antiprogrammed death-1

  • Tomoyuki MinowaEmail author
  • Junji Kato
  • Tokimasa Hida
  • Kohei Horimoto
  • Sayuri Sato
  • Masahide Sawada
  • Hisashi Uhara
Article
  • 2 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil–to–lymphocyte ratio in solid tumors: a systematic review and meta–analysis. J Natl Cancer Inst 2014; 106: dju124.CrossRefGoogle Scholar
  2. 2.
    Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta–analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1204–12.CrossRefGoogle Scholar
  3. 3.
    Fujisawa Y, Yoshino K, Otsuka A, et al. Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population. Br J Dermatol 2018; 179: 213–5.CrossRefGoogle Scholar
  4. 4.
    Nakamura Y, Kitano S, Takahashi A, et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016; 7: 77404–15.Google Scholar
  5. 5.
    Chasseuil E, Saint–Jean M, Chasseuil H, et al. Blood predictive biomarkers for nivolumab in advanced melanoma. Acta Derm Venereol 2018; 98: 406–10.CrossRefGoogle Scholar
  6. 6.
    Garnier M, Zaragoza J, Bénéton N, et al. High neutrophil–tolymphocyte ratio before starting anti–PD1 immunotherapy predicts poor outcome in patients with metastatic melanoma. J Am Acad Dermatol 2018; 79: 165–7.CrossRefGoogle Scholar
  7. 7.
    Minowa T, Kato J, Hida T, et al. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti–programmed death–1 therapy. J Dermatol 2018; 45: e250–1.CrossRefGoogle Scholar
  8. 8.
    Khoja L, Atenafu EG, Templeton A, et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab–treated cutaneous metastatic melanoma. Cancer Med 2016; 5: 2792–9.CrossRefGoogle Scholar
  9. 9.
    Failing JJ, Yan Y, Porrata LF, Markovic SN. Lymphocyte–to–monocyte ratio is associated with survival in pembrolizumab–treated metastatic melanoma patients. Melanoma Res 2017; 27: 596–600.CrossRefGoogle Scholar
  10. 10.
    Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 2016; 174: 146–51.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Tomoyuki Minowa
    • 1
    Email author
  • Junji Kato
    • 1
  • Tokimasa Hida
    • 1
  • Kohei Horimoto
    • 1
  • Sayuri Sato
    • 1
  • Masahide Sawada
    • 1
  • Hisashi Uhara
    • 1
  1. 1.Department of DermatologySapporo Medical University School of MedicineSapporo, HokkaidoJapan

Personalised recommendations